Omeros Corporation's SEC filings document the regulatory record of a commercial-stage biotechnology company focused on protein and small-molecule therapeutics, including YARTEMLEA, OMS1029 and programs in complement-mediated diseases, cancers, and addictive or compulsive disorders. Form 8-K reports cover operating and financial results, material-event disclosures, clinical and regulatory updates, material agreements, and capital-structure matters.
Proxy materials describe annual shareholder meeting mechanics, director elections, executive-compensation votes, board governance and related shareholder voting matters. The filing record also includes formal disclosure of the FDA approval of YARTEMLEA for TA-TMA and financial-condition information tied to Omeros' commercialization and development-stage pipeline.
Omeros Corp. (OMER) Chairman, CEO & President Gregory A. Demopulos received a direct grant of a performance stock option covering 500,000 common shares on October 28, 2026. The option has an exercise price of $17.88 per share and expires October 28, 2031. No portion was vested and no shares were issued on the grant date. Vesting is subject to four equal tranches, specified stock-price hurdles and continued service. Under the service schedule, 25% of each tranche becomes eligible for vesting on the first anniversary of the grant date, with the remainder eligible in equal monthly installments over the following 36 months.
Omeros Corporation granted its Chief Executive Officer, Gregory A. Demopulos, M.D., a performance-based stock option to purchase up to 500,000 common shares on October 28, 2026. The award is divided equally among four tranches, each tied to a stock-price hurdle of $25.00, $30.00, $35.00 or $40.00 per share, measured using the aggregate volume-weighted average price over 30 consecutive trading days during the five-year term. Continued service is also required.
For each tranche, 25% becomes eligible for vesting on the first anniversary of the grant date, with the remainder becoming eligible in equal monthly installments over the following 36 months. The exercise price is $17.88 per share, and the option expires October 28, 2031. No portion was vested and no shares were issued on the grant date.
OMEROS CORP (OMER) VP, Finance & CAO David J. Borges exercised options to acquire 10,000 shares on September 23, 2026, at $15.58 per share, and options for 5,000 shares each at $3.93 and $2.94 on September 22. He sold 10,000 shares on each date at $20.95 per share. Both sales were open-market sales under a Rule 10b5-1 trading plan adopted February 10, 2026.
OMEROS CORP officer David Borges gave notice of a proposed sale of 14,927 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $314,213.35. The notice lists September 23, 2026 as the approximate sale date. The remarks state that the securities to be sold were and will be received upon exercise of stock options over the next three months; acquisition and payment dates were and will be the dates of exercise/sale.
The notice also lists earlier sales as “10b5-1 Sales” for David Joseph Borges: 10,000 shares on September 22, 2026 for $209,500; 906 shares on August 24, 2026 for $17,304.60; 10,000 shares on August 21, 2026 for $189,500; and 5,000 shares on August 13, 2026 for $84,750.
OMEROS CORPORATION (OMER) has a notice from officer David Borges indicating an intent to sell 10,000 shares of common stock. The shares are to be obtained via exercise of stock options for cash on September 22, 2026, with Morgan Stanley Smith Barney LLC Executive Financial Services listed as broker.
The notice also lists prior Rule 10b5-1 plan sales of Omeros common stock by David Joseph Borges during the past three months, including transactions on August 13, 21, and 24, 2026, with sizes ranging from 906 to 10,000 shares.
For OMEROS CORP (OMER), VP and General Counsel Peter B. Cancelmo reported two exercise-and-sale transactions. On August 28 and August 31, 2026, he exercised stock options for a total of 50,000 shares of common stock at an exercise price of $2.94 per share and sold all 50,000 shares in the market at weighted average prices of $18.6451 and $18.5416, respectively. The sale prices are reported as weighted averages over multiple trades within disclosed intraday price ranges.
Omeros Corporation (OMER) insider Peter Brogan Cancelmo has filed a Rule 144 notice for a proposed sale of 25,000 shares of Omeros common stock through Morgan Stanley Smith Barney. The shares relate to an exercise of options under a registered plan, with an aggregate market value listed as $463,540. Omeros common shares outstanding are reported as 72,388,316 as of the notice date. The notice also lists a prior sale of 25,000 shares for $466,127.50 within the past three months.
OMEROS CORP (OMER) received a Form 144 notice from Peter Brogan Cancelmo covering a proposed sale of up to 25,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC, in connection with the exercise of options under a registered plan for cash, with a proposed sale date of August 28, 2026.
OMEROS CORP (OMER) director Arnold C. Hanish reported option exercises and related share sales. On August 26–27, 2026, he exercised stock options for 15,000 shares of common stock at exercise prices of $14.66 and $15.81 per share, then sold 15,000 shares in open-market transactions at weighted average prices between about $18.53 and $19.02 per share. A separate indirect holding of 12,400 shares is reported as held by the Arnold C. Hanish Living Trust, which has not sold these shares.
OMEROS CORPORATION (OMER) received a notice under Rule 144 that director Arnold C. Hanish intends to sell up to 10,000 shares of common stock. The shares relate to option exercises under a registered plan and are to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing also lists that, during the prior three months, Arnold Hanish sold 5,000 shares of OMEROS common stock for $94,132.50.